Trump may be mystery patient in odd case of 79yo getting experimental obesity drug
The patient was not recommended for bariatric surgery, given their age and other conditions. It was unclear whether the person would have been eligible for a trial. It’s also unclear if retatrutide would work in patients who have failed to see success with tirzepatide.
“Something very wrong”
The public notice of the expanded access is suspicious, omitting much of the information that such a notice would normally include, such as the conditions that might qualify a patient for such access.
“Only people in the know would be able to find this [notice], using the drug name,” Richard Klein, who helped launch the FDA’s expanded access program in the 1980s, told Stat. “There is something very wrong with the way this is listed because no one would know what it is from the listing, or what it’s for.”
Stat asked both the White House and the Department of Health and Human...
Copyright of this story solely belongs to arstechnica.com. To see the full text click HERE
